Newswise — TAMPA, Fla. — Patient-reported outcomes are important indicators of how cancer drugs impact patients’ lives. By assessing the benefits and risks of drugs from a patient’s perspective, scientists and physicians can improve the development of patient-centered drugs and care. In a recent study published in eClinicalMedicine, part of The Lancet Discovery Science, Moffitt Cancer Center researchers demonstrate that there is a significant unmet need for improved analyses and reporting of patient-reported outcomes in genitourinary cancer clinical trials.
Health care professionals have realized that how a disease and its treatment impact a patient’s life are critical factors to consider when choosing treatment. A therapy may improve survival; however, if its side effects are too great and impact a patient’s quality of life, that drug may not be an optimal choice. Patient-reported outcomes are reports from patients about their own health status and quality of life that take into account their disease, the treatment they are receiving, and other personal factors. Patient-reported outcomes can include questions from side effects of treatment to financial concerns and access to caregiver support.
The Moffitt researchers wanted to assess the quality of patient-reported outcomes data collected in clinical trials that led to the approval of genitourinary cancer therapies. Genitourinary cancers affect over 444,000 people each year in the United States. They are among the most common malignant diseases in men, including prostate, bladder and kidney cancers. Chemotherapy has traditionally been the standard treatment option for patients with genitourinary cancers; however, within the past 15 years, many new targeted treatment options have been approved based on improvements in outcomes such as overall survival and response rates. Patient-reported outcomes are often analyzed in cancer clinical trials but the quality of these analyses in genitourinary clinical trials is unknown.
The team conducted a systematic review of data that led to genitourinary cancer drug FDA approvals from February 2007 to July 2022 and identified 40 clinical trials that met inclusion criteria. They analyzed the clinical trial protocols and compared what was intended in the study to what patient-reported outcomes data was presented and published. The researchers then analyzed the quality of the patient-reported outcomes data based on a scoring scheme they developed.
The researchers found that only 67.5% of the trial publications reported patient-reported outcomes data, including 10% that reported preliminary patient-reported outcomes data in the primary clinical trial publication and 57.5% that reported patient-reported outcomes data in a secondary publication. Of the 40 clinical trials, 31 planned to collect patient-reported outcomes data, while nine did not. The median time between the primary clinical trial publication and the publication of the patient-reported outcome was 10.5 months. The researchers found that the type of patient-reported outcomes data that was collected, and the statistical analyses used to analyze the data varied greatly among the studies, and many trials still needed to perform a quality analysis. The mean quality score of the patient-reported outcomes data was 11.10 (range of 6–24) out of a possible 24 total points.
These combined data reveal that patient-reported outcomes data is often not collected in a timely manner or of the highest quality. The researchers hope their analysis will improve clinical trial design and approaches to collecting and analyzing patient-reported outcomes data to improve patient outcomes and quality of life.
“Our data showed a considerable gap in reporting patient-reported outcomes and in the quality of design and conduct of patient-reported outcomes-related trial endpoints. With the expanding array of therapies for genitourinary malignancies, the accessibility and clear presentation of patient-reported outcomes data are also essential for tailoring personalized treatment plans for patients, highlighting the crucial need for improved reporting and accessibility of this information,” explained Jad Chahoud, M.D., MPH, assistant member of the Department of Genitourinary Oncology at Moffitt.
This work was supported by the National Cancer Institute (P30-CA076292) and the R.S. Evans Foundation.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 56 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 9,000 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
###
Paravathaneni, M., Safa, H., Joshi, V. B., Tamil, M., Adashek, J. J., Ionescu, F., Shah, S., Chadha, J., Gilbert, S. M., Manley, B. J., Semaan, A., Jim, H., Kalos, D., Kim, Y. C., Spiess, P. E., & Chahoud, J. (2024). 15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis. eClinicalMedicine, 68, 102413. https://doi.org/10.1016/j.eclinm.2023.102413
RSS